# Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin

> **NCT00396071** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** vildagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00396071
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396071, "Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00396071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*